



Q4 2023 法人說明會

IR Contact/Spokesperson
Mandy Huang
mandy.huang@mbi.com.tw

SAFE HARBOR NOTICE

TCL's statements of its current expectations are forwardlooking statements subject to significant risks and uncertainties and actual results may differ materially from those contained in the forward-looking statements.


Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

膠原蛋白及玻尿酸生技醫療公司


股票代號 1783

員工數 150 人

2021 年營收 NTD 5.12 億元



膠原蛋白及玻尿酸產品應用



玻尿酸

骨科

關節內注射劑


眼科

眼科黏彈劑

醫美

皮膚填補劑

保健品



膠原蛋白

骨科

骨骼填補物

牙科

牙科填補物、傷口敷料

外科


傷口敷料、引導組織再生膜

保健品


專注於膠原蛋白及玻尿酸生技領域

營收分佈 依產品
Sales Breakdown - by Product


● HYALURONIC ACID RELATED ● COLLAGEN RELATED ● OTHER




Q1 2023



Q2 2023



Q3 2023




Q4 2023


營收分佈 依區域

Sales Breakdown - by Region


TAIWAN US EU CHINA ASIA




Q1 2023



Q2 2023



Q3 2023



Q4 2023

Q4 2023 財務總覽

Financial Review



第四季財務報表摘要

Consolidated Financial Report

(新台幣百萬)

	Q4 2023 Amount	%	Q3 2023 Amount	%	QoQ %	Q4 2022 Amount	%	YoY %
營業收入	149	100%	159	100%	-6%	164	100%	-9%
營業毛利	104	70%	108	68%	-4%	110	67%	-5%
營業費用	-70	-47%	-82	-52%	-15%	-61	-37%	15%
- 推銷費用	-36	-24%	-37	-23%	-3%	-32	-20%	13%
- 管理費用	-15	-10%	-20	-13%	-25%	-11	-7%	36%
- 研發費用	-19	-13%	-25	-16%	-24%	-17	-10%	12%
- 預期信用損失	0	0%	0	0%	-	-1	-1%	-100%
營業利潤	34	23%	26	16%	31%	49	30%	-31%
營業外收入	-10	-7%	29	18%	-134%	3	2%	-433%
所得稅費用	-6	-4%	-13	-8%	-54%	-9	-5%	-33%
稅後淨利	18	12%	42	26%	-57%	43	26%	-58%
淨利歸屬於母公司業主	18	12%	42	26%	-57%	43	26%	-58%
基本每股盈餘	0.19		0.47			0.40		

資產負債表摘要

Balance Sheet

(新台幣百萬)	Q4 2023 Amount	%	Q3 2023 Amount	%	Q4 2022 Amount	%
現金及約當現金	431	29%	421	27%	791	55%
應收帳款	88	6%	111	7%	99	7%
存貨	85	6%	97	6%	75	5%
不動產 廠房 及設備	889	60%	914	59%	435	30%
資產總計	1,493	100%	1,543	100%	1,448	100%
短期借款	-	0%	-	0%		0%
流動負債合計	132	9%	174	11%	152	10%
負債總計	132	9%	174	11%	152	10%
權益總計	1,361	91%	1,369	89%	1,296	90%

現金流量表摘要

Cash Flow Statement

(新台幣百萬)	Q4 2023 Amount	Q3 2023 Amount	Q4 2022 Amount
期初現金及約當現金	791	791	513
營業活動之淨現金流入(流出)	171	114	268
投資活動之淨現金流入(流出)	-490	-485	11
籌資活動之淨現金流入(流出)	-41	0	-1
匯率影響數	0	0	0
期末現金及約當現金	431	420	791
自由現金流	152	100	262

自由現金流=營運現金淨流入-資本支出

